Hyposmia in progressive supranuclear palsy

Movement Disorders

Volumn 25, Issue 5, 2010, Pages 570-577

  Silveira Moriyama, Laura ^a   Hughes, Graham ^b   Church, Alistair ^c   Ayling, Hilary ^d   Williams, David R ^a,e   Petrie, Aviva ^f   Holton, Janice ^a,d   Revesz, Tamas ^d   Kingsbury, Ann ^a   Morris, Huw R ^g   Burn, David J ^b   Lees, Andrew J ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c ROYAL GWENT HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ALFRED HOSPITAL   (Australia)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Olfaction; Parkinson's disease; Postmortem analysis; Smell; UPSIT

Indexed keywords

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN REGION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; FEMALE; HUMAN; HYPOSMIA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RATING SCALE; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NERVE DEGENERATION; OLFACTION DISORDERS; OLFACTORY PATHWAYS; RETROSPECTIVE STUDIES; ROC CURVE; SMELL; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 77951213318     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22688     Document Type: Article

References (41)

1. Steele JC, Richardson WS, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333-359.
2. Richardson WS, Steele JC, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of "heterogenous system degeneration" Trans Am Neurol Assoc 1963;88:25-29.
3. Albert ML, Feldman RG, Willis AL. The 'subcortical dementia' of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974;37:121-130.
4. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128:1247-1258.
5. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.
6. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988;38:1237-1244.
7. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008;63:167-173.
8. Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995;91:247-250.
9. Doty RL, Golbe LI, McKeown DA, Stern MB, Lehrach CM, Crawford D. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology 1993;43:962-965.
10. Muller A, Mungersdorf M, Reichmann H, Strehle G, Hummel T. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 2002;9:521-524.
11. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson- Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
13. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology 2000;55:1621-1626.
14. Fahn S, Elton RL,Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marden SD, Calne DB, Goldstein M, editors. Recents developments in Parkinson's disease. Florham Park: Macmillan Healthcare; 1987. p 153-163.
15. Cubo E, Stebbins GT, Golbe LI, et al. Application of the unified Parkinson's disease rating scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord 2000;15:276-279.
16. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
17. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984;32:489-502.
18. Petrie A, Sabin C. Multiple linear regression. In: Petrie A, Sabin C, editors. Medical statistics at a glance. Massachussetts: Blackwell Publishing Ltd; 2005. p 76-78.
19. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55:97-105.
20. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
21. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389-404.
22. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
23. Mai JK, Paxinos G, Assheuer JK, editors. Atlas of the human brain. San Diego: Elsevier Academic Press; 2003.
24. Price JL. Olfaction. In: Paxinos G, Mai JK, editors. The human nervous system. San Diego: Elsevier Academic Press; 2004. p 1197-1211.
25. de Silva R, Lashley T, Gibb G, et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 2003;29:288-302.
26. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
27. Silveira-Moriyama L, Guedes LC, Kingsbury A, et al. Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data. Neurology 2008;71:1021-1026.
28. Paviour DC, Winterburn D, Simmonds S, et al. Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing. Neurocase 2005;11:274-282.
29. Doty RL. Odor perception in neurodegenerative diseases. In: Doty RL, editor. Handbook of olfaction and gustation. Philadelphia: Marcel Dekker, Inc.; 2003. p 479-501.
30. Tsuboi Y, Wszolek ZK, Graff-Radford NR, Cookson N, Dickson DW. Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4. Neuropathol Appl Neurobiol 2003;29:503-510.
31. Murphy C, Jinich S. Olfactory dysfunction in Down's syndrome. Neurobiol Aging 1996;17:631-637.
32. Hemdal P, Corwin J, Oster H. Olfactory identification deficits in Down's syndrome and idiopathic mental retardation. Neuropsychologia 1993;31:977-984.
33. Warner MD, Peabody CA, Berger PA. Olfactory deficits and Down's syndrome. Biol Psychiatry 1988;23:836-839.
34. Wetter S, Murphy C. Individuals with Down's syndrome demonstrate abnormal olfactory event-related potentials. Clin Neurophysiol 1999;110:1563-1569.
35. Doty RL, Perl DP, Steele JC, et al. Olfactory dysfunction in three neurodegenerative diseases. Geriatrics 1991;46:S47-S51.
36. Luzzi S, Snowden JS, Neary D, Coccia M, Provinciali L, Lambon Ralph MA. Distinct patterns of olfactory impairment in Alzheimer's disease, semantic dementia, frontotemporal dementia, and corticobasal degeneration. Neuropsychologia 2007;45:1823-1831.
37. Muller A, Reichmann H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 2002;109:805-811.
38. Pardini M, Huey ED, Cavanagh AL, Grafman J. Olfactory function in corticobasal syndrome and frontotemporal dementia. Arch Neurol 2009;66:92-96.
39. Daniel SE, Hawkes CH. Preliminary diagnosis of Parkinson's disease by olfactory bulb pathology. Lancet 1992;340:186.
40. Silveira-Moriyama L, Petrie A, Williams DR, et al. The use of a colour coded probability scale to interpret smell tests in suspected Parkinsonism. Mov Disord 2009;24:1144-1153.
41. O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008;131:1362-1372.